A randomized, double-blind, placebo-controlled, parallel study to investigate the efficacy and safety of VSF-173 [Vanda Pharmaceuticals] and matching placebo in healthy male and female subjects with induced excessive sleepiness
Phase of Trial: Phase II
Latest Information Update: 03 Jul 2012
At a glance
- Drugs VSF 173 (Primary)
- Indications Hypersomnia
- Focus Therapeutic Use
- Sponsors Vanda Pharmaceuticals
- 03 Jul 2012 Actual initiation date (20 Apr 2007) added as reported by European Clinical Trials Database.
- 03 Jul 2012 Planned end date 20 Sep 2007 added as reported by European Clinical Trials Database.
- 01 Nov 2007 Status change from recruiting to completed.